Marios K Georgakis1, Paraskevi Panagopoulou2, Paraskevi Papathoma1, Athanasios Tragiannidis3, Anton Ryzhov4, Snezana Zivkovic-Perisic5, Sultan Eser6, Łukasz Taraszkiewicz7, Mario Sekerija8, Tina Žagar9, Luis Antunes10, Anna Zborovskaya11, Joana Bastos12, Margareta Florea13, Daniela Coza14, Anna Demetriou15, Domenic Agius16, Rajko M Strahinja17, Georgios Sfakianos18, Ioannis Nikas19, Sofia Kosmidis20, Evangelia Razis21, Apostolos Pourtsidis22, Maria Kantzanou1, Nick Dessypris1, Eleni Th Petridou23. 1. Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece. 2. Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece; Fourth Department of Pediatrics, Medical School, General Hospital "Papageorgiou", Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Second Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Greece. 4. National Cancer Registry of Ukraine, National Institute of Cancer, Kyiv, Ukraine. 5. Institute of Public Health of Serbia, Department for NCD Prevention and Control, Cancer Registry for Central Serbia, Belgrade, Serbia. 6. Izmir Cancer Registry, Izmir Hub, Izmir & Hacettepe University Institute of Public Health, Ankara, Turkey. 7. Greater Poland Cancer Registry, Department of Cancer Prevention and Epidemiology, Greater Poland Cancer Center, Poznan, Poland. 8. Croatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia; School of Public Health "Andrija Stampar", School of Medicine, University of Zagreb, Zagreb, Croatia. 9. Cancer Registry of Republic of Slovenia, Institute of Oncology, Ljubljana, Slovenia. 10. North Region Cancer Registry of Portugal (RORENO), Portuguese Oncology Institute of Porto, Portugal. 11. Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Childhood Cancer Subregistry of Belarus, Minsk, Belarus. 12. Central Region Cancer Registry of Portugal (ROR-Centro), Portuguese Oncology Institute of Coimbra, Portugal. 13. Regional Cancer Registry of Iasi, National Institute of Public Health, Iasi, Romania. 14. Regional Cancer Registry of Cluj, Oncological Institute "Ion Chiricuta", Cluj-Napoca, Romania. 15. Cyprus Cancer Registry-Health Monitoring Unit, Ministry of Health, Nicosia, Cyprus. 16. Malta National Cancer Registry, Department of Health Information and Research, Malta. 17. Institute of Public Health, Center for Disease Prevention and Control, Department for Epidemiology of NCDs, Cancer Registry, Podgorica, Montenegro. 18. Department of Neurosurgery, "Aghia Sophia" Children's Hospital, Athens, Greece. 19. Imaging Department, "Aghia Sophia" Children's Hospital of Athens, Athens, Greece. 20. Radiotherapy-Oncology Department, Hygeia Hospital, Athens, Greece. 21. Third Department of Internal Medicine-Oncology, Hygeia Hospital, Athens, Greece. 22. Department of Pediatric Hematology-Oncology, "Pan. & Agl. Kyriakou" Children's Hospital, Athens, Greece. 23. Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address: epetrid@med.uoa.gr.
Abstract
AIM: To present incidence of central nervous system (CNS) tumours among adolescents and young adults (AYAs; 15-39 years) derived from registries of Southern and Eastern Europe (SEE) in comparison to the Surveillance, Epidemiology and End Results (SEER), US and explore changes due to etiological parameters or registration improvement via evaluating time trends. METHODS: Diagnoses of 11,438 incident malignant CNS tumours in AYAs (1990-2014) were retrieved from 14 collaborating SEE cancer registries and 13,573 from the publicly available SEER database (1990-2012). Age-adjusted incidence rates (AIRs) were calculated; Poisson and joinpoint regression analyses were performed for temporal trends. RESULTS: The overall AIR of malignant CNS tumours among AYAs was higher in SEE (28.1/million) compared to SEER (24.7/million). Astrocytomas comprised almost half of the cases in both regions, albeit the higher proportion of unspecified cases in SEE registries (30% versus 2.5% in SEER). Similar were the age and gender distributions across SEE and SEER with a male-to-female ratio of 1.3 and an overall increase of incidence by age. Increasing temporal trends in incidence were documented in four SEE registries (Greater Poland, Portugal North, Turkey-Izmir and Ukraine) versus an annual decrease in Croatia (-2.5%) and a rather stable rate in SEER (-0.3%). CONCLUSION: This first report on descriptive epidemiology of AYAs malignant CNS tumours in the SEE area shows higher incidence rates as compared to the United States of America and variable temporal trends that may be linked to registration improvements. Hence, it emphasises the need for optimisation of cancer registration processes, as to enable the in-depth evaluation of the observed patterns by disease subtype.
AIM: To present incidence of central nervous system (CNS) tumours among adolescents and young adults (AYAs; 15-39 years) derived from registries of Southern and Eastern Europe (SEE) in comparison to the Surveillance, Epidemiology and End Results (SEER), US and explore changes due to etiological parameters or registration improvement via evaluating time trends. METHODS: Diagnoses of 11,438 incident malignant CNS tumours in AYAs (1990-2014) were retrieved from 14 collaborating SEE cancer registries and 13,573 from the publicly available SEER database (1990-2012). Age-adjusted incidence rates (AIRs) were calculated; Poisson and joinpoint regression analyses were performed for temporal trends. RESULTS: The overall AIR of malignant CNS tumours among AYAs was higher in SEE (28.1/million) compared to SEER (24.7/million). Astrocytomas comprised almost half of the cases in both regions, albeit the higher proportion of unspecified cases in SEE registries (30% versus 2.5% in SEER). Similar were the age and gender distributions across SEE and SEER with a male-to-female ratio of 1.3 and an overall increase of incidence by age. Increasing temporal trends in incidence were documented in four SEE registries (Greater Poland, Portugal North, Turkey-Izmir and Ukraine) versus an annual decrease in Croatia (-2.5%) and a rather stable rate in SEER (-0.3%). CONCLUSION: This first report on descriptive epidemiology of AYAs malignant CNS tumours in the SEE area shows higher incidence rates as compared to the United States of America and variable temporal trends that may be linked to registration improvements. Hence, it emphasises the need for optimisation of cancer registration processes, as to enable the in-depth evaluation of the observed patterns by disease subtype.